Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone
Lynn R. Webster(Adherent Technologies (United States)), Michael A. Eldon(Nektar Therapeutics (United States)), Carlo J. Di Fonzo(Nektar Therapeutics (United States)), Suresh Siddhanti(Amgen (United States)), Aleksandrs Odinecs(Nektar Therapeutics (United States)), Jack E. Henningfield(Univates), Lin Lü(Nektar Therapeutics (United States)), August R. Buchhalter(Pinney Associates (United States))
Cited by 29
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Biochemical verification of tobacco use and cessation
|Nicotine & Tobacco Research|2002|1.8k
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Blood Cannabinoids. I. Absorption of THC and Formation of 11-OH-THC and THCCOOH During and After Smoking Marijuana*
|Journal of Analytical Toxicology|1992|520
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504